Leavell Investment Management Inc. Has $5.44 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Leavell Investment Management Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,006 shares of the company’s stock after buying an additional 291 shares during the quarter. Leavell Investment Management Inc.’s holdings in Eli Lilly and Company were worth $5,438,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LLY. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $29,000. Core Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new stake in Eli Lilly and Company in the second quarter valued at $32,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $37,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock worth $1,066,841,316 over the last three months. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 0.1 %

Eli Lilly and Company stock traded up $1.20 during midday trading on Thursday, hitting $931.58. 3,047,801 shares of the stock were exchanged, compared to its average volume of 3,102,805. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $966.10. The stock has a market capitalization of $885.38 billion, a price-to-earnings ratio of 137.16, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The business’s 50-day moving average price is $875.61 and its 200-day moving average price is $801.22. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, August 5th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,023.00 price target on shares of Eli Lilly and Company in a research note on Friday, July 5th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $948.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.